In Part 1 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how cost discipline, manufacturing shifts, and portfolio resets are reshaping large pharma.

This week, following up on our recent post about Merck, we had Eyes On their recent bid for Cidara Therapeutics. This time, the acquisition is made to diversify their portfolio further, adding an antiviral asset for Influenza prophylaxis. This asset, CD 388, could provide a new class of prophylaxis, outside of the current vaccines area.

At PharmaTell we keep Eyes on Strategic moves within the market. This week we're diving into Merck & Co's plans for the future. With the upcoming patent expiry for Keytruda, they are planning to bolster their pipeline with new products and indications via internal development and M&A.

Lately we've had Eyes On: Clinical Data, FDA news, M&A, and more. Read more about uniQure's AMT-130 data for Huntington's Disease, Roche's acquisition of 89bio for MASH, JnJ's Iconic Advance Data for Psoriasis, Lundbeck's CRL letter for PTSD, and the latest buzz around acetaminophen.

We've been keeping Eyes On the updates coming out along with the 2Q25 Results. Lots of news on strategic Plans, M&A, Clinical Data, and more. 

Lately, we've kept our Eyes On Sarepta Therapeutics and their discussions with the US FDA regarding their gene therapy Product Elevidys, their pipeline platform. All of this, plus the management shuffles at the FDA itself, has created quite a stir in the industry.

 This month we've had Eyes On The BBB and potential timing and impact on the BioPharma sector. This is a dynamic area, with many different news bytes daily, let us know what you'v e seen and what sources you are following.

This week we've kept Eyes On the MFN and Tariff news, plus the Moderna x HHS Break-up and the Lilly x SiteOne Deal. The BioPharma Marketplace is in flux and we're watching to see how everyone is adapting and re-aligning their strategies.

We're catching up on the latest news and views surrounding the BioPharma Industry & Tariffs.

Just two weeks after our initial blogpost was published, 23andMe has made headlines again — this time for being acquired by Regeneron Pharmaceuticals in a deal valued at $256 million.

We've been keeping Eyes On Regulatory news, both in the US and Europe. We're sharing a few of the updates from the past few weeks on approval timing, staffing changes, clinical results, international company coalitions, and more.

23andMe files for Chapter 11 bankruptcy and seeks a court-managed sale, co-founder and CEO Anne Wojcicki will step down

Spark Therapeutics, the gene therapy division that Roche purchased for $4.3 billion in 2019, has undergone a significant reorganisation.

Lenacapavir from Gilead Sciences has shown promise when dosed even more widely apart - only once a year...

JnJ, Legend expanding cell therapy capacity.

For ten titans of industry in 2025, the U.S. patent runway is coming to a close.

This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

Here at PharmaTell, we have Eyes on FDA Approvals for 2025. Below, we share the monthly Novel Drug and Biologic License Application Approval

We've had Eye's On the JP Morgan Healthcare Conference, Lifesciences 2024 restructuring stats, and some new drug development partnerships.

According to an annual PwC study released in December, the amount of M&A activity in the pharmaceutical and life sciences sectors in 2024...